{
  "report_rows": [
    {
      "kpi": "Q2 2026 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$25.34B vs. cons $25.03B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.90 vs. cons $2.86",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 MedTech sales",
      "prediction": "IN-LINE",
      "answer": "pred ~$8.94B vs. cons $8.90B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Operational sales",
      "prediction": "BETTER",
      "answer": "guide ~$100.6B vs. cons $100.5B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Reported adjusted EPS",
      "prediction": "BETTER",
      "answer": "guide ~$11.62 vs. cons $11.58 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted pretax operating-margin expansion",
      "prediction": "UNCHANGED",
      "answer": "guide ~+50 bps vs. cons +50 bps (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.4,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.6,
  "day5_path": "FADE",
  "day5_rationale": "5-day residual ~+0.6% vs. day-1 residual +1.4%: a modest beat and raise should lift estimates, but limited second-half EPS flow-through and some FX contribution to the sales raise imply only small out-period revisions, allowing the high-valuation initial reaction to partially fade.",
  "day5_confidence": "MEDIUM"
}